These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of myelodysplastic syndromes in the geriatric patient. Ritchie EK; Lachs MS Curr Hematol Malig Rep; 2009 Jan; 4(1):3-9. PubMed ID: 20425432 [TBL] [Abstract][Full Text] [Related]
3. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Stauder R Ann Hematol; 2012 Sep; 91(9):1333-43. PubMed ID: 22547053 [TBL] [Abstract][Full Text] [Related]
4. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753 [TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes in the United States: an update for clinicians. Troy JD; Atallah E; Geyer JT; Saber W Ann Med; 2014 Aug; 46(5):283-9. PubMed ID: 24716735 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Burgstaller S; Wiesinger P; Stauder R Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843 [TBL] [Abstract][Full Text] [Related]
8. Advances in supportive care of myelodysplastic syndromes. Gordon MS Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713 [TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
10. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311 [TBL] [Abstract][Full Text] [Related]
11. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
12. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826 [TBL] [Abstract][Full Text] [Related]
13. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113 [TBL] [Abstract][Full Text] [Related]
14. Incorporating novel agents in the treatment of myelodysplastic syndromes. Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566 [TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. Aul C; Giagounidis A; Germing U; Ganser A Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275 [TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes: the challenge of developing clinical guidelines and supportive care strategies for a rare disease. Kurtin SE Clin J Oncol Nurs; 2012 Jun; 16 Suppl():5-7. PubMed ID: 22641280 [TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes: more prevalent than we know. Sandhu SK; Sekeres MA Geriatrics; 2008 Nov; 63(11):10-7. PubMed ID: 18998762 [TBL] [Abstract][Full Text] [Related]
19. Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. Breccia M; Molica M; Zacheo I; Alimena G Expert Opin Pharmacother; 2014 Aug; 15(11):1621-30. PubMed ID: 24989987 [TBL] [Abstract][Full Text] [Related]